Nabi Biopharmaceuticals says it has decided to push ahead with studies into a potential vaccine for staph bacteria after a late-stage trial failed a primary endpoint. Nabi formed an advisory panel to investigate the trial failure of StaphVAX. The panel concluded that the antibodies generated for the late-stage trial were inferior to the antibodies generated by vaccine lots in earlier studies.
"Today's announcement marks a new beginning for our Gram-positive program, which is much enhanced by the knowledge we've gained about the bacteria and immune response," said Nabi CEO Thomas H. McLain. "Moving forward, we have a clear development pathway on which to readily advance our vaccine and antibody products toward commercialization."
- here's the AP report for more